1619-62-1Relevant articles and documents
REACTION MECHANISMS FOR ELECTROCHEMICAL CARBON-SKELETON REARRANGEMENT AS CATALYZED BY HYDROPHOBIC VITAMIN B12 IN NONAQUEOUS MEDIA
Murakami, Yukito,Hisaeda, Yoshio,Tashiro, Takako,Matsuda, Yoshihisa
, p. 555 - 558 (1986)
Reaction mechanisms for the controlled-potential electrolysis of 2,2-bis(ethoxycarbonyl)-1-bromopropane at -1.0, -1.5, and -2.0 V vs.SCE as catalyzed by a hydrophobic vitamin B12 were clarified.
A Convenient Synthesis of Diethyl Dialkyl- and Dibenzylmalonates via Extractive Alkylation
Singh, Rajendra K.
, p. 54 - 55 (1985)
-
Methylcorrinoids methylate radicals - Their second biological mode of action?
Mosimann, Herve,Kraeutler, Bernhard
, p. X393-395 (2000)
-
Characterization of a Simple Vitamin B12 Model Complex and Its Catalysis in Electrochemical Carbon-Skeleton Rearrangement
Murakami, Yukito,Hisaeda, Yoshio,Fan, Sheng-Di
, p. 655 - 658 (1987)
The electrochemical carbon-skeleton rearrangement reaction of 2,2-bis(ethoxycarbonyl)-1-bromopropane was catalyzed by the cobalt complex of 2,10-diethyl-3,9-dipropyl-1,4,8,11-tetraazaundeca-1,3,8,10-tetraene-1,10-diol, which was characterized by ESR spectroscopy and cyclic voltammetry.
Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups
Jiang, Yingnan,Zhang, Ke,Gao, Suyu,Wang, Guihua,Huang, Jian,Wang, Jinhui,Chen, Lixia
, (2016/07/06)
Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.